QUESTIONS
Common questions, answered to the edge of the evidence
Every answer below stops where the published literature stops, and says so rather than filling the space.
What does BPC-157 do in the body?
In animals, it appears to speed tissue repair by encouraging the growth of new blood supply into damaged tissue. The best-characterised route runs through a receptor called VEGFR2 on the cells lining blood vessels, with downstream Akt and nitric-oxide signalling; the same work reported greater vessel density and faster restoration of blood flow in a rat hind limb with a blocked artery [4]. In rats it accelerated healing of a fully cut Achilles tendon [6] and reduced gastric ulcer area [5]. What it does in a human body has not been established. As of 2025 reviews only three small pilot studies have examined it in people, and rigorous large trials are lacking [2].
Is BPC-157 a growth hormone?
No. It is a fifteen-amino-acid peptide derived from a protein found in gastric juice, and it is not a hormone, not growth hormone, and not a growth-hormone-releasing agent. The point of confusion is real but narrower than the claim: part of its proposed repair mechanism involves sensitising the growth-hormone receptor in tendon cells, which is a local effect on how those cells respond to a hormone already present, not the release of a hormone into circulation. Its documented mechanism targets are VEGFR2, endothelial nitric oxide synthase, the growth-hormone receptor in tendon fibroblasts, and the FAK-paxillin complex [4].
Does BPC-157 damage the liver?
There is no evidence that it does, and there is also very little evidence about it either way, which is the more accurate answer. The one human safety report on this desk gave intravenous BPC-157 at up to 20 mg to two healthy adults and found no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers [1]. Two participants and a single administration cannot establish organ safety. Since no large or long human study exists [2], the honest position is that the liver question is unanswered rather than answered reassuringly.
What does retatrutide do?
In clinical trials it produced large reductions in body weight and improvements in blood sugar and liver fat. In a 48-week Phase 2 trial of 338 adults with obesity, the highest amount tested produced a mean body-weight change of -24.2 percent against -2.1 percent on placebo [11]. In 281 adults with type 2 diabetes over 36 weeks it lowered HbA1c by 2.02 percentage points at week 24 and body weight by 16.94 percent at week 36 [12]. A substudy of 98 people with fatty liver disease found liver fat down 82.4 percent at 24 weeks at the highest amount, with 86 percent reaching a normal level [10]. All of those are surrogate measures; no outcome trial has reported.
How does retatrutide work?
It activates three receptors with one molecule: GLP-1, GIP and glucagon. The GLP-1 and GIP arms reduce appetite, slow stomach emptying and improve glucose-dependent insulin release. The glucagon arm, which sounds counterintuitive for a metabolic drug, adds energy expenditure and fat mobilisation when it operates alongside the other two, so the compound acts on intake and expenditure at once. Structural work published in 2024 resolved it bound to all three receptors and measured the engagement as uneven: roughly 8.9-fold more potent than native GIP at the GIP receptor but 0.3-fold and 0.4-fold at the glucagon and GLP-1 receptors [9]. Which arm contributes what share of the effect has not been separated experimentally.
Is retatrutide FDA approved?
No. It is investigational and in Phase 3 trials, and it has not been approved by the FDA or any other regulator. That has two consequences worth keeping distinct. First, every figure published about it comes from clinical trial reports rather than from labelling a regulator has reviewed and argued over. Second, there is no legitimate supply route outside a trial, so material sold as research-grade retatrutide has unverified identity, concentration and sterility [8][11]. The Phase 3 programme and the dedicated cardiovascular and kidney outcome trials are described as ongoing [8], which is the single most load-bearing word in any summary of this compound.
What is NAD supplement used for?
It is marketed for ageing, energy and metabolic health, on the reasoning that tissue NAD+ falls with age while enzymes that need it, including the sirtuins and the DNA-repair enzyme PARP1, compete for a shrinking pool against the NAD-consuming enzyme CD38 [16]. What human trials have demonstrated is narrower than the marketing. Oral precursors reliably raise NAD+ in blood: nicotinamide riboside by 22, 51 and 142 percent at three ascending amounts over eight weeks [17], and NMN significantly at every amount tested over 60 days, alongside improved walking distance and quality-of-life scores [14]. A 2025 review of the human evidence concluded that clinical efficacy has been limited and tissue-level data remain sparse [13].
What is the downside of taking NAD+?
The trials summarised here reported no safety issues at the amounts tested [14][17], so the main downsides are not toxicity but uncertainty and product quality. Plain oral NAD+ is poorly taken up intact, which is why precursors are the rational oral form and why NAD+ capsules are widely argued to be the least defensible of the three products sold. Intravenous NAD+ rests on minimal controlled evidence, clears rapidly from plasma, and can cause chest or abdominal discomfort, flushing and nausea if infused too quickly. A compounded NAD+ injection has been recalled at Class I level for elevated bacterial endotoxin. A theoretical concern also exists in cancer, since NAD+ supports proliferating cells.
Is it safe to take NAD daily?
The published trials used daily oral precursor regimens and reported no safety signal within their windows: nicotinamide riboside at 100 to 1000 mg daily for eight weeks, with no flushing, no significant difference in adverse events against placebo, and no rise in LDL cholesterol [17]; NMN at 300 to 900 mg daily for 60 days with no safety issues at any amount [14]; and NMN at 250 mg daily for ten weeks [15]. The gap is duration, not signal. The longest of those studies ran ten weeks, against a hypothesis about what happens across decades, so a daily regimen has an eight-to-ten-week safety record and nothing beyond it. This site recommends no regimen to anyone.
What is PT-141?
PT-141 is bremelanotide, a synthetic cyclic peptide of seven amino acids built as an analogue of alpha-melanocyte-stimulating hormone. It was approved by the FDA in June 2019 for acquired, generalised hypoactive sexual desire disorder in premenopausal women, at a 1.75 mg subcutaneous amount taken as needed, no more than one in 24 hours and no more than eight in a month, with a terminal half-life of about 2.7 hours [22]. Material sold as PT-141 research chemical is a separate thing from the approved product and sits outside that framework, with no oversight of identity, purity or concentration.
What does the PT-141 peptide do?
It acts on the brain rather than on blood vessels, switching on melanocortin receptors, chiefly MC4R, that are concentrated in the hypothalamus and limbic system and sit upstream of sexual desire. That central mechanism is what distinguishes it from PDE-5 inhibitors, which work peripherally on vascular smooth muscle [22]. Beyond that, the mechanism is genuinely open. A 2022 crossover imaging study in 31 premenopausal women found increased sexual desire for up to 24 hours and altered amygdala-insula connectivity [19], while a 2025 study in female Syrian hamsters found no enhancement of sexual reward and no change in melanocortin-receptor expression in the mesolimbic dopamine system, arguing against the classic reward-circuit account [18].
What is PT-141 used for?
Its approved use is one narrow indication: acquired, generalised low sexual desire in premenopausal women. That approval rests on two identical Phase 3 randomised trials enrolling 1,267 participants, which over 24 weeks produced an integrated improvement of +0.35 on the desire domain of the Female Sexual Function Index and a reduction of -0.33 in desire-related distress, both statistically significant [20]. Use in men, in postmenopausal women, or to enhance performance is off-label and was not what that programme studied [22]. The largest community discussing the compound therefore sits outside the population the evidence describes, which is the central gap on its page.